We have accumulated an extensive patent portfolio in the course of our research in the areas of Multivalent Bispecific Antibodies, F-18 Labeling, DOCK-AND-LOCK™, Antibody-Drug Conjugates, Antibody-Drug Conjugate Linker, and T-cell Redirecting Antibodies, which we believe constitutes a very valuable business asset.
The major patents highlighted in the chart below relate primarily to our therapeutic product candidates. Additional patents have been filed to extend the patent life on some of these products, but there can be no assurance that these will issue as filed.
|Program & Product Group||Description/Targeted Antigen||Patent Expiration||Major Jurisdictions|
|CD22 - Program – Epratuzumab||Unlabeled Antibody CD22||2016 – 2023||USA, Europe, Japan|
|CD20 Program – Veltuzumab||Unlabeled Antibody CD20||2023 – 2029||USA, Europe, Japan|
|CD74 Program – Milatuzumab||Unlabeled Antibody CD74||2023 – 2024||USA, Europe, Japan|
|Antibody-Drug Conjugate Program||Antibody-SN-38 Conjugates||2033||USA, Europe, Japan|
|Subcutaneous Formulation||All Antibodies||2032||USA, Europe, Japan|
|DNLTM Program – TF2||Bispecific Antibody CEACAM5||2026||USA, Europe, Japan|
|F-18 Labelling Technology||F-18 labeling of proteins and peptides for PET imaging||2027 – 2028||USA, Europe, Japan|